Mosquito-borne diseases -- particularly Eastern equine encephalomyelitis and West Nile encephalitis -- pose a significant threat to horses, and owners need more education on the importance of vaccination, says Peter Timoney, chair in equine veterinary science at the University of Kentucky's Gluck Equine Research Center. "There is need for an ongoing concerted effort, utilizing all avenues of communication including social media, to alert horse owners of the dangers of these two vector-borne diseases and of the importance of vaccination as an effective means of prevention and averting the losses that continue to occur every year in unprotected horses," Dr. Timoney wrote in Equine Disease Quarterly.
Researchers analyzed data from the TECOS trial involving 13,616 adults with diabetes and cardiovascular disease from 38 countries and found that only 29.9% of patients met all five secondary prevention targets -- blood pressure and lipid control, use of aspirin and prophylactic medications, and not smoking -- compared with nearly three-quarters who met four of the targets. The findings, published in Circulation and presented at the Heart in Diabetes Clinical Education Conference, revealed that non-smoking status was the most often met target, while BP control was the target met least often.
An MDVIP Fat IQ Survey conducted by Ipsos Public Affairs revealed that 56% of US adults failed the quiz, compared with less than 1% of those who got an A grade. Researchers also found that 90% of respondents said they would be influenced to lose weight if a physician told them they have a serious health risk, while 83% would be motivated if a physician advised them to lose weight.
Primary care providers and cardiologists are advised to consider prescribing newer classes of diabetes drugs, such as liraglutide or empagliflozin, to help patients with type 2 diabetes and heart disease reduce their cardiovascular risk, according to a study presented at the Heart in Diabetes Clinical Education Conference. "If you look at the big picture, on the upside you have cardiovascular event reduction in high-risk patients, glucose lowering, weight loss, blood pressure lowering, beneficial lipid profile, renal protection, very low risk of hypoglycemia, the convenience of not needing to dose adjust even for renal disease," said presenter Dr. Ildiko Lingvay.
Patients with diabetes and heart disease may better manage their conditions with the help of wearable technologies, such as continuous glucose monitoring devices, the Zio patch and insulin delivery devices, Dr. George Grunberger said during a presentation at the Heart in Diabetes Clinical Education Conference. "The main issue now is the device connectivity, data analysis and feedback by professionals back to patients," Grunberger said.
A study in the Journal of the American College of Cardiology found non-vitamin K antagonist oral anticoagulants may be more beneficial for women with atrial fibrillation than men, lowering their risk of intracranial hemorrhage and all-cause mortality. The study team called for the inclusion of more women in cardiovascular studies.
Researchers at the National Institute of Allergy and Infectious Diseases who used SPECT with a CD4-specific imaging probe found that macaques with simian immunodeficiency virus who underwent long-term antiretroviral therapy had "suboptimal" and smaller CD4+ T-cell pool reconstitution in the lymph nodes, but similar T-cell pools in the gut, compared with healthy macaques, suggesting that the gut may not be the target of SIV infection. The approach, described in JCI Insight, may prompt immune reconstruction analysis in humans with HIV after receiving traditional and experimental therapies, researchers said.
A study in npj Parkinson's Disease showed that PET with three different radioligands was able to visualize cardiac inflammation and oxidative stress in rhesus macaques with Parkinson's disease, and monkeys that were given pioglitazone had significantly increased nerve function recovery. The findings suggest that PET may be used not only in testing Parkinson's treatments but also in enabling increased understanding of the early mechanisms of heart nerve damage, lead researcher Jeanette Metzger said.
The FDA approved Pfizer and Astellas Pharma's Xtandi, or enzalutamide, as a treatment for men with non-metastatic castration-resistant prostate cancer. The drug was previously approved to treat metastatic castration-resistant prostate cancer.
The FDA lifted its clinical hold placed on the Advaxis Phase I/II study for ADXS11-001, or axalimogene filolisbac, in combination with Imfinzi, or durvalumab, being developed to treat HPV-associated squamous cell carcinoma of the head and neck and advanced, recurrent or refractory cervical cancer. New guidelines for early detection and treatment of safety-related events have been implemented by the company.
- Page 1